News & Updates

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.

In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.

Combined treatment with ATRQβ-001 and ADRQβ-004 vaccines shows potential as a therapeutic strategy for hypertension management, according to the preliminary findings of a study.

HER2-positive metastatic breast cancer (mBC) patients who had been treated with trastuzumab emtansine continue to enjoy survival benefits with trastuzumab deruxtecan (TD) relative to those who received treatment of physician’s choice (TPC), as shown by the updated results of the DESTINY-Breast (DB)-02 study. TD also boasts of a manageable safety profile, with no long-term toxicity.

Among smokers with chronic obstructive pulmonary disease (COPD), use of varenicline seems better than bupropion in normal metabolizers, but bupropion displays similar efficacy and less side effects in slow metabolizers, reports a study.